CASI Pharmaceuticals Inc (NASDAQ:CASI)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday.

Separately, Maxim Group set a $4.00 price objective on shares of CASI Pharmaceuticals and gave the company a “buy” rating in a report on Monday.

CASI Pharmaceuticals (NASDAQ:CASI) opened at 1.72 on Wednesday. The stock’s market capitalization is $85.07 million. CASI Pharmaceuticals has a 12-month low of $0.58 and a 12-month high of $1.76. The stock’s 50 day moving average is $1.38 and its 200 day moving average is $1.22.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.05. Analysts forecast that CASI Pharmaceuticals will post ($0.23) EPS for the current year.

In other CASI Pharmaceuticals news, Director Wei-Wu He acquired 1,871,605 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The shares were acquired at an average cost of $1.19 per share, for a total transaction of $2,227,209.95. Following the completion of the acquisition, the director now directly owns 24,698 shares of the company’s stock, valued at approximately $29,390.62. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

5 Day Chart for NASDAQ:CASI

Receive News & Stock Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.